# CR-CP Life Science Fund

> CR-CP Life Science Fund is a VC fund backing Health Care and Biotechnology. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hong Kong, Hong Kong
- Total investments: 15
- Last investment: Nov 2022
- Lead investor: 47%
- Last updated: Aug 2026

CR-CP Life Science Fund is a joint venture set up by China Resources Group and Charoen Pokphand Group. This firm invests in life science companies that develop drugs, cell therapies, medical devices, and smart healthcare technology.

## Contacts

5 contacts available for CR-CP Life Science Fund. Shizune tracks 2 team members at CR-CP Life Science Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cr-cp-life-science-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 67% |
| Biotechnology | 9 | 60% |
| Medical | 5 | 33% |
| Therapeutics | 3 | 20% |
| Medical Device | 3 | 20% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 47% |
| Series C | 4 | 27% |
| Series E | 2 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 6 | 40% |
| Israel | 2 | 13% |
| United States | 2 | 13% |
| Belgium | 1 | 7% |
| Singapore | 1 | 7% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Da Liu | Managing Director | 3 | https://shizune.co/investors/profile/da-liu |
| Jason Zhou | CEO & Managing Director | 4 | https://shizune.co/investors/profile/jason-zhou-bb9f |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M | Series B | Nov 03, 2022 |  |
| NuProbe | An early stage molecular diagnostics company. | $50M | Series B | Jun 02, 2022 |  |
| Yueer Gene | Yueer is a genetic screening and diagnosis service provider, focusing on applying new genetic technology & international big data algorithms | $50M | Series B | Jun 02, 2022 |  |
| Mirxes | MiRXES offers discover, develop, and deliver accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases, and make them accessible to all. | $87M | Series C | Feb 22, 2022 |  |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $22.2M | Series B | Oct 28, 2021 |  |
| Mirxes | MiRXES offers discover, develop, and deliver accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases, and make them accessible to all. | $77M | Series C | Jul 08, 2021 |  |
| EyeYon | EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M | Series C | Mar 15, 2021 |  |
| ReViral | ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates,enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds. | $44M | Series C | Aug 25, 2020 |  |
| BELKIN Vision | BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $12.3M | Series B | Jul 21, 2020 |  |
| New Horizon Health | New Horizon Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancerscreening into thousands of households so that the public can enjoy convenient and efficient health services . | $30M | Series E | Jul 10, 2020 |  |

10 of 15 investments shown.

## Co-investors
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 4 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 3 deals together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 3 deals together
- [Temasek](https://shizune.co/investors/profile/temasek) — VC Fund, 3 deals together
- [Charoen Pokphand Group](https://shizune.co/investors/profile/charoen-pokphand-group) — VC Fund, 2 deals together
- [CICC Healthcare Investment Fund](https://shizune.co/investors/profile/cicc-healthcare-investment-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does CR-CP Life Science Fund invest in?

CR-CP Life Science Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CR-CP Life Science Fund?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CR-CP Life Science Fund?

The team at CR-CP Life Science Fund includes Da Liu (Managing Director) and Jason Zhou (CEO & Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co